IGC Pharma (IGC) FCF Margin (2010 - 2025)

IGC Pharma (IGC) has reported FCF Margin for 16 consecutive years, with 717.8% the latest figure, recorded in Q3 2025.

• On a quarterly basis, FCF Margin fell 46901.0% year-over-year to 717.8% in Q3 2025; TTM through Sep 2025 was 391.78%, a 3180.0% increase from a year earlier, with the FY2026 full-year figure at 386.12%, down 5.0% from the prior year.
• FCF Margin was 717.8% for Q3 2025 at IGC Pharma, down from 328.72% in the prior quarter.
• Over five years, FCF Margin peaked at 183.39% in Q1 2024 and troughed at 4167.86% in Q3 2021.
• A 5-year average of 1066.76% and a median of 671.69% in 2022 frame the typical range for FCF Margin.
• The widest YoY moves for FCF Margin: up 613201 bps in 2021, down 197026 bps in 2021.
• Over 5 years, FCF Margin stood at 1724.65% in 2021, then jumped by 61 bps to 671.69% in 2022, then dropped by 21 bps to 811.27% in 2023, then soared by 36 bps to 522.96% in 2024, then plunged by 37 bps to 717.8% in 2025.
• The last three FCF Margin figures came in at 717.8% (Q3 2025), 328.72% (Q2 2025), and 226.67% (Q1 2025), per Business Quant data.